The observation that a decreased p16INK4a level, which leads to increased activation of Cdk4, correlates with PAX3-FOXO1 expression in ARMS tumor formation [4] would predict that pharmacologic inhibition of Cdk4 is effective for treating ARMS. Here, CDKN2A is linked to alveolar rhabdomyosarcoma.